The persistence of vibegron and the reasons for withdrawal from treatment of treatment-naive female patients with overactive bladder in the real-world clinical setting

The persistence of vibegron and the reasons for withdrawal from treatment of treatment-naive female patients with overactive bladder in the real-world clinical setting - Persistence and reasons for withdrawal of vibegron

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038342

Enrollment

100

Registered

2019-10-21

Start date

2019-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Treatment-naive Japanese female patients who visited the hospital for the symptoms of OAB and were clinically diagnosed with OAB

Exclusion criteria

Exclusion criteria: Patients with urinary tract infection, large postvoid residual volume, a previous treatment history for OAB, and contraindications to use of vibegron

Design outcomes

Primary

Measure	Time frame
The persistence of treatment with vibegron and the reasons for withdrawal from the treatment	—

Countries

Japan

Contacts

Public ContactYoshinori Tanaka

Hokkaido Prefectural Esashi Hospital Division of Urology

rinoshiyokanata@me.com0139-52-0036

Outcome results